Huntington's Disease — CPB 0614 | AETNA Coverage Update

Aetna modified CPB 0614 for Huntington's disease, effective February 27, 2026. Every intervention listed under this policy is classified as experimental, investigational, or unproven — meaning Aetna will not reimburse any of them.

Aetna, a CVS Health company, updated CPB 0614, its Huntington's disease coverage policy, to reflect its current position on a wide range of diagnostics and treatments. This policy covers 49 CPT codes and 21 HCPCS codes — including CPT 78608 and 78609 for PET imaging, CPT 70554 for functional MRI, CPT 90867–90869 for transcranial magnetic stimulation, and CPT 61863, 61864, 61867, and 61868 for deep brain stimulation. If your team bills any of these codes for Huntington's disease patients under ICD-10 G10, this coverage policy affects your revenue cycle today.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Huntington's Disease — CPB 0614
Policy Code	CPB 0614
Change Type	Modified
Effective Date	February 27, 2026
Impact Level	High
Specialties Affected	Neurology, nuclear medicine, clinical genetics, behavioral health, interventional neurosurgery, stem cell/transplant programs
Key Action	Audit all claims for G10 and Z13.858 against this exclusion list before submitting — every listed intervention is non-covered

---

Aetna Huntington's Disease Coverage Criteria and Medical Necessity Requirements 2026

The Aetna Huntington's disease coverage policy under CPB 0614 takes a hard line: there are no covered interventions listed in this policy. The entire policy is structured as an exclusion list. Aetna does not recognize medical necessity for any of the diagnostics or treatments enumerated here.

This is significant for billing teams. Normally, a clinical policy bulletin draws a line between covered and non-covered services. CPB 0614 draws no such line. There is no approved treatment pathway, no prior authorization route that unlocks coverage, and no clinical criteria a patient can meet to get these services reimbursed.

The policy scope is broad. It covers imaging (functional MRI, PET, MR spectroscopy), laboratory biomarkers (interleukins, microRNAs, neurofilament light chain, tau), surgical interventions (deep brain stimulation, pallidotomy, neural grafts), and drug therapies (bupropion via HCPCS S0106, levocarnitine via J1955, minocycline via J2265). It also covers emerging gene therapy approaches, stem cell transplantation (CPT 38230, 38232, 38240, 38241), and wearable digital sensors for disease monitoring.

If your practice treats Huntington's disease patients and bills Aetna, the absence of any covered indication here should be your planning baseline.

---

Aetna Huntington's Disease Exclusions and Non-Covered Indications

This is where CPB 0614 lives entirely. The policy is an exclusions-only document.

Diagnostics and Biomarkers

Aetna considers all of the following experimental for Huntington's disease:

The biomarker exclusions are notable because they block diagnostic coding strategies you might use to track a patient's trajectory. Billing CPT 83529 for IL-6 in an HD context or running molecular pathology under CPT 81401 or 81405 will trigger a claim denial under this policy.

Treatments and Interventions

The treatment exclusion list is extensive. It covers pharmacological, surgical, rehabilitative, and investigational categories:

Surgical and neurostimulation: Deep brain stimulation (CPT 61863, 61864, 61867, 61868 and related neurostimulator codes), pallidotomy (CPT 61720), transcranial magnetic stimulation (CPT 90867, 90868, 90869, 0310T), transcranial direct current stimulation (CPT 64550), and electroconvulsive therapy (CPT 90870) are all non-covered.

Transplant and regenerative: Fetal striatal transplantation, neural grafts (CPT 64885, 64886), stem cell transplantation (CPT 38230, 38232, 38240, 38241, 38243), and combination gene/stem cell therapy are all excluded. CAR-T codes 38225–38228 appear in the related codes section.

Gene therapy: HTT-lowering therapies, gene silencing through RNA interference, and Ionis-HTTRx (an HTT-targeting antisense oligonucleotide) are all classified as experimental.

Drug therapies: Bupropion (HCPCS S0106), levocarnitine (J1955), minocycline (J2265), coenzyme Q10, creatine, cysteamine, donepezil, and several others are non-covered for this indication.

Rehabilitative and behavioral: Dance therapy and music therapy (HCPCS G0176), rhythmic auditory cueing, and neurotrophic factor infusions are also excluded.

Wearable sensors: Wearable and portable digital sensors for clinical management — including detection of early disease manifestations and disease fluctuations — are classified as experimental.

The real issue here is that this list includes interventions clinicians actively use for HD patients in practice. Deep brain stimulation, TMS, and some of these medications appear in treatment protocols. The gap between clinical use and Aetna's coverage position is wide. Your billing team needs to understand that clinical use does not equal covered use under this policy.

---

Coverage Indications at a Glance

---

Aetna Huntington's Disease Billing Guidelines and Action Items 2026

This policy's effective date of February 27, 2026 means you should already be acting. Here's what to do now.

Copy Action Items

If your practice runs a significant volume of HD patients across neurology, genetics, and behavioral health, talk to your compliance officer before the effective date about how this policy intersects with your current service mix. The breadth of the exclusions here creates real exposure.

---

CPT, HCPCS, and ICD-10 Codes for Huntington's Disease Under CPB 0614

All codes below are classified as non-covered / experimental under CPB 0614. There are no covered codes in this policy.

Non-Covered CPT Codes — Experimental Under CPB 0614

Non-Covered HCPCS Codes — Experimental Under CPB 0614

Key ICD-10-CM Diagnosis Codes

Code	Description Copy
G10	Huntington's disease
Z13.858	Encounter for screening for other nervous system disorders [Huntington's disease]

---